Therefore, both YY1 and survivin serve a pro-tumorigenic role in aggressive B-NHLs, particularly in B-cell lymphomas (BLs), and survivin is likely a good potential diagnostic and prognostic biomarker for chemotherapy responses in patients with NHL [109]. This evidence concerns the gene YY1 and B-cell non-Hodgkin lymphoma.